Systematic or Test-Guided Treatment for Tuberculosis in HIV-Infected Adults.

Area of Science:

• Infectious Diseases
• Immunology
• Clinical Trials

Background:

• High burden of tuberculosis (TB) and human immunodeficiency virus (HIV) co-infection poses significant mortality risks.
• HIV-infected adults often initiate antiretroviral therapy (ART) with severe immunosuppression (CD4+ T-cell count <100 cells/mm³).
• Tuberculosis and invasive bacterial diseases are leading causes of death in this population post-ART initiation.

Purpose of the Study:

• To compare the efficacy and safety of empirical tuberculosis treatment versus test-guided treatment in severely immunocompromised, ART-naive HIV-infected adults.
• To evaluate the impact of each treatment strategy on mortality and invasive bacterial disease rates at 24 and 48 weeks.
• To assess the incidence of drug-related adverse events associated with each approach.

Main Methods:

• A 48-week randomized controlled trial involving HIV-infected adults with CD4+ T-cell counts below 100 cells/mm³ across four countries.
• Participants were assigned to either systematic empirical tuberculosis treatment or treatment guided by diagnostic screening (Xpert MTB/RIF, urine LAM, chest X-ray).
• Primary endpoint: composite of death from any cause or invasive bacterial disease within 24 or 48 weeks.

Main Results:

• No significant difference in the composite endpoint of death or invasive bacterial disease at 24 weeks (19.4% vs. 20.3%) or 48 weeks (12.8% vs. 13.3%) between systematic and guided treatment groups.
• Systematic treatment significantly reduced the probability of tuberculosis diagnosis by week 24 (3.0% vs. 17.9%).
• Systematic treatment was associated with a higher incidence of grade 3 or 4 drug-related adverse events (17.4% vs. 7.2%) and more serious adverse events.

Conclusions:

• Empirical tuberculosis treatment is not superior to test-guided treatment for reducing mortality or invasive bacterial disease in severely immunocompromised, ART-naive HIV-infected adults.
• Systematic treatment strategies increased the risk of significant adverse events compared to test-guided approaches.
• Clinical decisions should weigh the potential benefits of early empirical treatment against the increased risk of adverse events in this vulnerable population.